These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 25764941)

  • 21. [Treatment of B-cell lymphoma with a chimeric anti-CD20 monoclonal antibody(rituximab)].
    Tobinai K
    Nihon Rinsho; 2002 Jan; 60(1):95-9. PubMed ID: 11808346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Construction and Characterization of 1F5 Chimeric Anti-CD20 Monoclonal Antibodies: An Efficient Splicing by Overlap Extension-polymerase Chain Reaction Technique.
    Khademi F; Mohammadi P; Mostafaei A
    Iran J Allergy Asthma Immunol; 2021 Apr; 20(2):205-220. PubMed ID: 33904679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concepts in radiotherapy and immunotherapy: anti-CD20 mechanisms of action and targets.
    Maloney DG
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S19-26. PubMed ID: 15786022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.
    Davis TA; Czerwinski DK; Levy R
    Clin Cancer Res; 1999 Mar; 5(3):611-5. PubMed ID: 10100713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs.
    Demidem A; Lam T; Alas S; Hariharan K; Hanna N; Bonavida B
    Cancer Biother Radiopharm; 1997 Jun; 12(3):177-86. PubMed ID: 10851464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies.
    Robak T
    Curr Opin Investig Drugs; 2009 Jun; 10(6):588-96. PubMed ID: 19513948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels.
    Stanglmaier M; Faltin M; Ruf P; Bodenhausen A; Schröder P; Lindhofer H
    Int J Cancer; 2008 Sep; 123(5):1181-9. PubMed ID: 18546289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].
    Iguchi T; Miyazawa K; Okabe S; Kawakubo K; Shimamoto T; Kuriyama Y; Ito Y; Kimura Y; Ohyashiki K; Serizawa H; Iwaya K; Mukai K
    Rinsho Ketsueki; 2004 Oct; 45(10):1129-34. PubMed ID: 15553050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma.
    Roguedas AM; Watier H; Paintaud G; de Muret A; Vaillant L; Machet L
    Br J Dermatol; 2005 Mar; 152(3):541-4. PubMed ID: 15787825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimization of canine CD20 chimeric antigen receptor T cell manufacturing and in vitro cytotoxic activity against B-cell lymphoma.
    Sakai O; Igase M; Mizuno T
    Vet Comp Oncol; 2020 Dec; 18(4):739-752. PubMed ID: 32329214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Tumor Microenvironment Regulates CD19 and CD20 Immunotherapy for Lymphoma.
    Lykken JM; Tedder TF
    Cancer J; 2015; 21(4):351-6. PubMed ID: 26222089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
    Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC
    J Immunother; 2001; 24(3):263-71. PubMed ID: 11394505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monoclonal antibodies in the treatment of lymphoid malignancies.
    Tsirigotis P; Economopoulos T
    J Steroid Biochem Mol Biol; 2008 Feb; 108(3-5):267-71. PubMed ID: 17935974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Development of a Recombinant scFv Monoclonal Antibody Targeting Canine CD20 for Use in Comparative Medicine.
    Jain S; Aresu L; Comazzi S; Shi J; Worrall E; Clayton J; Humphries W; Hemmington S; Davis P; Murray E; Limeneh AA; Ball K; Ruckova E; Muller P; Vojtesek B; Fahraeus R; Argyle D; Hupp TR
    PLoS One; 2016; 11(2):e0148366. PubMed ID: 26894679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.
    Iida S; Misaka H; Inoue M; Shibata M; Nakano R; Yamane-Ohnuki N; Wakitani M; Yano K; Shitara K; Satoh M
    Clin Cancer Res; 2006 May; 12(9):2879-87. PubMed ID: 16675584
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells.
    Hayden-Ledbetter MS; Cerveny CG; Espling E; Brady WA; Grosmaire LS; Tan P; Bader R; Slater S; Nilsson CA; Barone DS; Simon A; Bradley C; Thompson PA; Wahl AF; Ledbetter JA
    Clin Cancer Res; 2009 Apr; 15(8):2739-46. PubMed ID: 19351771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Rituximab and hematological malignancy].
    Hatake K; Mishima Y; Terui Y
    Nihon Rinsho; 2004 Jul; 62(7):1321-4. PubMed ID: 15283150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hydrogen deuterium exchange mass spectrometry identifies the dominant paratope in CD20 antigen binding to the NCD1.2 monoclonal antibody.
    Uhrik L; Hernychova L; Muller P; Kalathiya U; Lisowska MM; Kocikowski M; Parys M; Faktor J; Nekulova M; Nortcliffe C; Zatloukalova P; Ruetgen B; Fahraeus R; Ball KL; Argyle DJ; Vojtesek B; Hupp TR
    Biochem J; 2021 Jan; 478(1):99-120. PubMed ID: 33284343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.
    Bornstein GG; Quéva C; Tabrizi M; van Abbema A; Chavez C; Wang P; Foord O; Ahluwalia K; Laing N; Raja S; Wen S; Green LL; Yang X; Webster C; Stewart R; Blakey D
    Invest New Drugs; 2010 Oct; 28(5):561-74. PubMed ID: 19626278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.